Oncolys BioPharma Inc.
Research Oncolys BioPharma Inc. (4588.T) on Bullrun: market cap JPY 152.50B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4588.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 152.50B
- Financial periodFY2025
- RevenueJPY 28.55M
- Revenue growth-9.0%
- Net income-JPY 2.06B
- Free cash flow-JPY 1.94B
- Gross margin100.0%
Valuation Snapshot
latest market cap is JPY 152.50B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 28.55M | -JPY 2.06B | -JPY 1.94B | 100.0% | -80 | JPY 3.67B | JPY 320.02M | JPY 4.00B |
| FY2024 | JPY 31.38M | -JPY 1.68B | -JPY 2.02B | 100.0% | -77.17 | JPY 2.41B | JPY 324.64M | JPY 2.75B |
| FY2023 | JPY 63.04M | -JPY 1.94B | -JPY 1.34B | 48.5% | -108.92 | JPY 1.53B | JPY 315.17M | JPY 1.47B |
| FY2022 | JPY 976.18M | -JPY 1.15B | -JPY 1.72B | 34.7% | -66.31 | JPY 1.71B | JPY 393.66M | JPY 2.16B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 152.50B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Oncolys BioPharma Inc.
Oncolys BioPharma Inc. engages in the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia. Its product pipeline comprises Telomelysin (OBP-301), an oncolytic viral immunotherapy which is in phase II clinical trial to treat gastric cancer; phase I clinical trial for the treatment of HCC; and treatment of esophageal cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Oncolys BioPharma Inc.'s market cap?
Oncolys BioPharma Inc.'s market capitalization is JPY 152.50B.
What does Oncolys BioPharma Inc. do?
Oncolys BioPharma Inc. engages in the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia. Its product pipeline comprises Telomelysin (OBP-301), an oncolytic viral immunotherapy which is in phase II clinical trial to treat gastric cancer; phase I clinical trial for the treatment of HCC; and treatment of esophageal cancer.